Depomed Issues Statement on ISS Report
The ISS recommendation relates only to calling the Special Meetings, and ISS has not made any recommendation regarding Horizon's proposal concerning directors or its exchange offer. In its report ISS states, "…ISS explicitly reserves judgment on the advisability of Horizon's offer until shareholders have the benefit of additional information about the Nucynta relaunch, and are presented with the opportunity to vote on that question directly."1
The ISS recommendation does not change the fact that we believe Horizon's offer does not reflect the value inherent in
As announced on
We strongly believe
The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including, but not limited to, those related to
Important Additional Information
This communication does not constitute an offer to buy or solicitation of an offer to sell any securities.
1 Permission to quote published materials was neither sought nor obtained.
Certain Information Regarding Participants
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/depomed-issues-statement-on-iss-report-300149716.html
Minimum 15 minutes delayed.